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LETTERS TO THE EDITOR 
Morbidity and Mortality with PUVA: Colonic Cancer 
(The Reply to this letter appeared in /ID 92646, 1989.) 
To the Editor: 
Cancer, according to some authors, has a lower incidence in patients 
with psoriasis [ 11. In the recent article from Stern et al [2], there was 
a significant increase in the incidence of colonic cancer after ten 
years of prospective study of a cohort of 1380 patients with psoriasis 
who had received photochemotherapy (PUVA). There may be an 
explanation for this unexpected finding from what is already known 
about the association between ulcerative colitis and psoriasis, and 
the risk of colonic cancer in ulcerative colitis. 
In a prospective study of skin disease in 142 patients with inflam- 
matory bowel disease, Verbov [3] showed a 7.5% prevalence of 
psoriasis in ulcerative colitis, which is substantially higher than the 
estimated prevalence of psoriasis in North-West Europeans, rated at 
1.5% -2.5% [4,5]. Yates et al [6] subsequently confirmed a signifi- 
cantly greater prevalence of psoriasis (5.7%) in ulcerative colitis 
than in the control group (1.50/) o , and an increased prevalence in 
first-degree relatives of patients with inflammatory bowel disease. It 
has therefore been suggested that there is a relationship between 
psoriasis and inflammatory bowel disease which may be explained 
by shared genetic factors or histocompatibility antigen linkage. 
As the risk of colonic cancer in patients with ulcerative colitis is 
between five and ten times greater than in the general population 
[7], it is tempting to speculate that there is a higher incidence of 
colonic cancer in the PUVA follow-up study owing to a preponder- 
ance of patients with ulcerative colitis in the psoriasis group. 
Unless the authors are able to establish the number of patients 
with ulceraive colitis in their study and control groups, this infor- 
mation should be collated from further large studies of morbidity 
and mortality in psoriatic patients. 
Christopher C. Harland, M.A., M.B., M.R.C.P. 
University Hospital 
Nottingham, U.K. 
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HNK-1 Antigen is Not Specific for Natural Killer Cells 
To the Editor: 
We were interested to read the article by Habets et al [l] and the 
subsequent correspondence published in the October 1988 issue [2, 
31 regarding natural killer (NK) cells around basal cell carcinomas 
(BCCs) and the suitability of the HNK-1 antigen as a marker for 
such cells. We agree with Manara that the HNK-1 antigen is not 
NK cell specific. The nomenclature committee at the recent 5th 
NK International Workshop, March 1988 [4] defined NK cells as 
commonly having CD16 (Leu 11) and NKH-1 (Leu 19) antigens; 
HNK-1 antigen was not a defining feature. 
Both Habets and Manara suggest further studies into the presence 
of CD16 and NKH-1 antigens to clarify the possible role of NK 
cells in defense against BCC. We have just completed such a study 
detailing reactivity of cells with Leu 7, Leu 11, and Leu 19 antibod- 
ies in a range of benign and malignant epidermal tumors (38 cases) 
and inflammatory dermatoses (20 cases). 
HNK-1 (Leu 7)-positive cells were found in all cases of tumors 
and dermatoses, whereas CD16 (Leu ll)- and NKH-1 (Leu 19)- 
positive cells showed a much more restricted tissue distribution 
with positive cells mainly associated with cases of squamous cell 
carcinoma and keratoacanthoma. Comparison of serial sections 
showed a clear disparity between positive cells using Leu 7 and Leu 
1 l/Leu 19. As the majority of cells in peripheral blood that demon- 
strate NK activity share the CD3 - ve, CD16 i- ve, NKH-1 posi- 
tive phenotype, these findings further suggest that cutaneous Leu 
7 + ve cells are predominantly cross-reacting T lymphocytes and 
not true NK cells. The restricted distribution of CD16/NKH-1 
positive cells around the squamoproliferative lesions of squamous 
cell carcinoma and keratoacanthoma is intriguing and may suggest a 
specific role for NK effector cells in these squamoproliferative le- 
sions. In no case did CD16/NKH-1 positive cells constitute more 
than 5% of the infiltrate, although the effector functions of NK 
cells may be a qualitative rather than a quantitative phenomenon [5]. 
We regard detection of the HNK-1 antigen by the antibody Leu 
7 as being insufficiently specific to be used as a marker for NK cells 
in cutaneous tissue and regard the detection of the more specific 
CD16 and NKH-1 antigens as being both theoretically and practi- 
cally superior for the purposes of cutaneous NK cell studies. 
Andrew C. Markey, M.B., M.R.C.P. 
Donald M. MacDonald, M.A., M.B., F.R.C.P. 
Department of Dermatology 
Guy’s Hospital 
London SE1 9RT 
U.K. 
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